# Human Genetics in Atherosclerosis: From Targets to Drugs

**A Scientific Conference, Co-hosted by Amgen and Stanford Medicine**

**Monday, August 21, 2017**

**8:00 a.m. – 5:00 p.m.**

**McCaw Hall at the Frances C. Arrillaga Alumni Center, Stanford University**

## Time | Activity/Topic | Details/Speaker
--- | --- | ---
8:00 a.m. | Registration Opens | Light breakfast provided (coffee, pastries)
8:30 a.m. | Welcome | Aarif Khakoo, M.D.  
Vice President, Cardiometabolic Disorders, Amgen  
Joseph C. Wu, M.D., Ph.D  
Director, Stanford University Cardiovascular Institute

### Session 1: The Role of Human Genetics in Target Discovery

*Session Chair: Vicki Parikh, M.D., Division of Cardiovascular Medicine, Stanford University*

8:45 a.m. | Keynote Address: Genetics of Common Diseases | Kári Stefánsson, M.D., Dr. Med.  
Vice President, deCODE Genetics

9:30 a.m. | Genetic Mechanisms of Coronary Disease: What Can We Learn From Genome-Wide Studies | Tom Quertermous, M.D., Ph.D.  
Professor of Cardiovascular Medicine, Stanford

10:00 a.m. | Break for Partial Solar Eclipse  
Refreshments | Limited number of protective eyewear will be provided

10:25 a.m. | Mendelian Randomization to Predict Causality of Cardiovascular Drug Targets Break | Erik Ingelsson, M.D., Ph.D.  
Professor of Cardiovascular Medicine, Stanford

10:50 a.m. | The Role of Efferocytosis in the Heritable Component of Atherosclerosis | Nick Leeper, M.D., Associate Professor of Vascular Surgery and Cardiovascular Medicine, Stanford

11:15 a.m. | TTC39B: a GWAS Hit for HDL With Multiple Metabolic Phenotypes in Mice and Therapeutic Potential | Alan Tall, M.B.B.S.  
Professor of Medicine, Columbia University

11:45 a.m. | Panel Discussion | Participants include speakers above and Helina Kassahun, M.D., Clinical Research Medical Director, Cardiovascular TA, Amgen

12:15 p.m. | Lunch |

### Session 2: Translating Human Genetics to Therapies

*Session Chair: Fatima Rodriguez, M.D., Division of Cardiovascular Medicine, Stanford University*

1.15 p.m. | ANGPTL4: Lessons Learned While Developing GWAS-Based Therapeutics | Brandon Ason, Ph.D.  
Sr. Scientist, Cardiometabolic Disorders, Amgen

1:45 p.m. | Familial Hypercholesterolemia (FH): The Epitome of Personalized Medicine | Josh Knowles, M.D., Ph.D.  
Assistant Professor of Cardiovascular Medicine, Stanford
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m.</td>
<td>PCSK9 Synthesis Inhibition via RNA Interference: Reducing the Burden of LDL-C Management</td>
<td>Clive Meanwell, M.B., Ch.B., M.D. C.E.O., The Medicines Company</td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td>PCSK9 Inhibition and the Genetics of Familial Hypercholesterolemia</td>
<td>Scott M. Wasserman, M.D. Vice President, Cardiovascular TA, Amgen</td>
</tr>
<tr>
<td>3:15 p.m.</td>
<td>Break</td>
<td>Refreshments</td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td>Panel Discussion</td>
<td>Participants include speakers above and Kenneth Mahaffey, M.D., Vice Chair of Medicine for Clinical Research in the Department of Medicine, Stanford University</td>
</tr>
<tr>
<td>4:00 p.m.</td>
<td>Closing Remarks</td>
<td>Simon Jackson, Ph.D. Scientific Director, Cardiometabolic Disorders, Amgen Josh Knowles, M.D., Ph.D. Assistant Professor of Cardiovascular Medicine, Stanford</td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td>Networking until 5:00 p.m.</td>
<td>Cocktails and Hors d’oeuvres</td>
</tr>
</tbody>
</table>